JP2016169175A - 腸内細菌叢改善剤 - Google Patents
腸内細菌叢改善剤 Download PDFInfo
- Publication number
- JP2016169175A JP2016169175A JP2015049134A JP2015049134A JP2016169175A JP 2016169175 A JP2016169175 A JP 2016169175A JP 2015049134 A JP2015049134 A JP 2015049134A JP 2015049134 A JP2015049134 A JP 2015049134A JP 2016169175 A JP2016169175 A JP 2016169175A
- Authority
- JP
- Japan
- Prior art keywords
- intestinal
- acetylglucosamine
- glucosamine
- bacterial flora
- intestinal bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 30
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 14
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 24
- 229950006780 n-acetylglucosamine Drugs 0.000 claims abstract description 24
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims abstract description 23
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims abstract description 23
- 241000894006 Bacteria Species 0.000 claims abstract description 19
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 17
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 16
- 229960002442 glucosamine Drugs 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 244000005709 gut microbiome Species 0.000 claims description 10
- 241000186000 Bifidobacterium Species 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 9
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- BWSIKGOGLDNQBZ-LURJTMIESA-N (2s)-2-(methoxymethyl)pyrrolidin-1-amine Chemical compound COC[C@@H]1CCCN1N BWSIKGOGLDNQBZ-LURJTMIESA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 4
- 241000238557 Decapoda Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 241001655328 Bifidobacteriales Species 0.000 description 3
- 241001112724 Lactobacillales Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- -1 inorganic acid salts Chemical class 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102100036495 Di-N-acetylchitobiase Human genes 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001228709 Suruga Species 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003014 ion exchange membrane Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
[1] N−アセチルグルコサミン、グルコサミン及びその塩から選ばれた少なくとも1種を有効成分とすることを特徴とする腸内細菌叢改善剤。
[2] 腸内細菌叢を多様化させる作用を有するものである前記[1]記載の腸内細菌叢改善剤。
[3] 腸内の善玉菌を相対的に増加させる作用を有するものである前記[1]又は[2]記載の腸内細菌叢改善剤。
[4] 前記善玉菌がビフィドバクテリウム目(Bifidobacteriales)の細菌である前記[3]記載の腸内細菌叢改善剤。
・被検物質
(1)グルコサミン塩酸塩(焼津水産化学工業株式会社、エビ由来、純度98%以上)
(2)N−アセチルグルコサミン(焼津水産化学工業株式会社、エビ・カニ由来、純度95%以上)
(1)老化促進モデルマウス(SAMP/1マウス):日本エスエルシー株式会社から15週齢のマウスを購入して使用
(2)自然加齢マウス(ICRマウス):宮城大学食産業学部ファームビジネス学科動物遺伝育種学研究室から分譲されたものを使用
供試動物のSAMP/1マウスは3ヵ月間、ICRマウスは6ヵ月間馴致したのち、試験に使用した。水は自由飲水で、飼料は市販飼料である「ラボMRストック」(商品名、日本農産工業株式会社)を給餌した。明暗は12時間で切り替え、床替えは週1回行い、1ケージに1頭という個別飼育を行った。SAMP/1マウスの区分けは1区:水投与、2区:グルコサミン塩酸塩投与、3区:N−アセチルグルコサミン投与とし、各区5頭(n=5)で行ったが、実験中に2区と3区で1頭ずつ死亡したため、1区はn=5、2区はn=4、3区はn=4で行った。ICRマウスの区分けも同様に、1区:水投与、2区:グルコサミン塩酸塩投与、3区:N−アセチルグルコサミン投与とし、1区、2区、3区共にn=5で行った。
被検物質の投与量としては、年齢65−70歳、平均体重62kgの一般人男性が、1日当たりに摂取する量、すなわち、グルコサミン塩酸塩は1日当たり1500mg、N−アセチルグルコサミンは1日当たり1000mgを想定し、マウスの体重で換算した量を投与するように蒸留水に溶かして投与試料とした。調製した投与試料を、1mLシリンジで100μL計量し、胃ゾンデ針を装着して、マウスに経口で強制投与した。投与は毎日正午に1回(24時間に1回)行い、8週間継続して連続投与を行った。
投与開始より8週間後、マウスを麻酔下に屠殺し、開腹して大腸管を採取した。糞便は、大腸管から直接1.5mLチューブに採取し、−30℃で凍結した。この凍結サンプルを室温にて解凍し、常法に従いDNAを抽出、精製して、T-RFLP(Terminal restriction fragment length polymorphism)解析に供した。なお、T-RFLP解析は、下記Nagashimaらの方法(以下参照)に基づく解析を、株式会社テクノスルガ・ラボに委託した。
K. Nagashima et al., Phylogenetic Analysis of 16S Ribosomal RNA Gene Sequences from Human Fecal Microbiota and Improved Utility of Terminal Restriction Fragment Length Polymorphism Profiling, Bioscience and Microflora, Vol. 25, 2006, No. 3, pp.99-107.
下記表5に示されるように、水投与区と比較し、グルコサミン塩酸塩投与区及びN−アセチルグルコサミン投与区でClostridiales目及びLactobacillales目の相対的な割合が顕著に低下した。また、グルコサミン塩酸塩投与区においてBifidobacteriales目の相対的な割合が顕著に増加した。
下記表6に示されるように、水投与区と比較し、グルコサミン塩酸塩投与区およびN−アセチルグルコサミン投与区でClostridiales目及びLactobacillales目の相対的な割合が顕著に低下した。また、N−アセチルグルコサミン投与区においてビフィドバクテリウム目(Bifidobacteriales)の相対的な割合が顕著に増加した。
配列番号1:16SリボソームRNA遺伝子の種特異的領域のPCR増幅のための蛍光標識フォワードプライマー;5’HEX-labeled 516f(5’-TGCCAGCAGCCGCGGTA-3’;E. coli positions 516-532)
配列番号2:16SリボソームRNA遺伝子の種特異的領域のPCR増幅のためのリバースプライマー;1510r(5’-GGTTACCTTGTTACGACTT-3’;E. coli positions 1510-1492)
Claims (4)
- N−アセチルグルコサミン、グルコサミン及びその塩から選ばれた少なくとも1種を有効成分とすることを特徴とする腸内細菌叢改善剤。
- 腸内細菌叢を多様化させる作用を有するものである請求項1記載の腸内細菌叢改善剤。
- 腸内の善玉菌を相対的に増加させる作用を有するものである請求項1又は2記載の腸内細菌叢改善剤。
- 前記善玉菌がビフィドバクテリウム目(Bifidobacteriales)の細菌である請求項3記載の腸内細菌叢改善剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015049134A JP6511878B2 (ja) | 2015-03-12 | 2015-03-12 | 腸内細菌叢改善剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015049134A JP6511878B2 (ja) | 2015-03-12 | 2015-03-12 | 腸内細菌叢改善剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016169175A true JP2016169175A (ja) | 2016-09-23 |
JP6511878B2 JP6511878B2 (ja) | 2019-05-15 |
Family
ID=56983205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015049134A Active JP6511878B2 (ja) | 2015-03-12 | 2015-03-12 | 腸内細菌叢改善剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6511878B2 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62198366A (ja) * | 1986-02-27 | 1987-09-02 | Natl Food Res Inst | キチン分解物の食品素材 |
-
2015
- 2015-03-12 JP JP2015049134A patent/JP6511878B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62198366A (ja) * | 1986-02-27 | 1987-09-02 | Natl Food Res Inst | キチン分解物の食品素材 |
Non-Patent Citations (2)
Title |
---|
BRYON W. PETSCHOW ET AL.: "Response of Bifidobacterium Species to Growth Promoters in Human and Cow Milk", PEDIATRIC RESEARCH, vol. 29(2), JPN6018046641, 1991, pages 208-213 * |
藤田親代: "ビフィズス菌因子並びにビフィズス菌製剤による人工栄養児腸内菌叢に及ぼす影響", 東邦医学会雑誌, vol. 8(2), JPN6018046642, 1961, JP, pages 360-392 * |
Also Published As
Publication number | Publication date |
---|---|
JP6511878B2 (ja) | 2019-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10226489B2 (en) | Composition of bacteroides thetaiotaomicron for immune modulation | |
Sumon et al. | Growth performance, digestive enzyme activity and immune response of Macrobrachium rosenbergii fed with probiotic Clostridium butyricum incorporated diets | |
Geraylou et al. | Effects of arabinoxylan-oligosaccharides (AXOS) on juvenile Siberian sturgeon (Acipenser baerii) performance, immune responses and gastrointestinal microbial community | |
Gopalakannan et al. | Inhibitory activity of probiotic Enterococcus faecium MC13 against Aeromonas hydrophila confers protection against hemorrhagic septicemia in common carp Cyprinus carpio | |
EP3133152B1 (en) | Novel bacteriophage, and composition containing same | |
TW201143631A (en) | Novel Enterococcus faecium LJS-01 and its use as probiotic | |
CN107073049B (zh) | 益生菌和益生元组合物 | |
Daly et al. | Bacterial sensing underlies artificial sweetener‐induced growth of gut L actobacillus | |
Ghasemi et al. | The effects of a synbiotic containing Enterococcus faecium and inulin on growth performance and resistance to coccidiosis in broiler chickens | |
EP3478082A1 (en) | Composition for treatment and/or nutrition of poultry | |
Amenyogbe et al. | Probiotic potential of indigenous (Bacillus sp. RCS1, Pantoea agglomerans RCS2, and Bacillus cereus strain RCS3) isolated from cobia fish (Rachycentron canadum) and their antagonistic effects on the growth of pathogenic Vibrio alginolyticus, Vibrio harveyi, Streptococcus iniae, and Streptococcus agalactiae | |
JP2010161944A (ja) | 新型カゼイ菌の亜種(sg96)及びこれを含有する菌抑制組成物及びその用途 | |
JP4565057B2 (ja) | イムノグロブリンa誘導能の高い新規乳酸菌 | |
JPH0984529A (ja) | 微生物由来のマンナンを含む家畜および家禽用飼料 | |
JP6511878B2 (ja) | 腸内細菌叢改善剤 | |
JP2012180288A (ja) | 抗菌剤 | |
JP7262391B2 (ja) | フソバクテリウム属細菌および/またはステレラ属細菌の菌数抑制剤 | |
TWI816432B (zh) | 一種強化魚類成長與健康效益之沙福芽孢桿菌及其應用 | |
AL-SHAMMARI et al. | Some of prebiotic and probiotic in Fish Aquaculture. | |
JP7228367B2 (ja) | ルミノコッカス属細菌の菌数抑制剤 | |
AU2018205072B2 (en) | Immune modulation | |
Limbu et al. | Role of Probiotics and Prebiotics in Animal Nutrition | |
JP2020097558A (ja) | ティザレラ属細菌の菌数抑制剤 | |
TWI750342B (zh) | 包含菌株之組合物及其用途、製法及產品 | |
이준영 | Comparative Genomic Analysis of Probiotic Properties of Host-Adapted Lactobacillus spp. Isolated from Pigs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180309 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180402 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190312 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190325 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6511878 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20190906 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |